Coronary heart disease
Conditions
Interventions
Group 1:oarl ticagrelor
Group 2:clopidogrel
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Healthy volunteers aged 18 to 40 years old; 2. Subjects are volunteer to participate in the clinical trials and sign the informed consent. Vital signs, physical examination, laboratory and electrocardiogram examinations should be performed before the trial.
Exclusion criteria
Exclusion criteria: 1. Medical examination does not meet the inclusion criteriafor example, Platelet110umol/L; Uric acid> 0.42mol/L; Abnormal coagulation. Heart rate<50bpm; BMI<18.5kg/m2 or =24kg/m2; weight<50Kg; 2. A clear medical history of neuropsychiatric, cardiovascular, kidney, liver, digestive, respiratory, metabolic or blood systems, or other significant diseases; 3. Gastrointestinal, intracranial, intraocular, retroperitoneal or spinal cord bleeding within 6months; History of trauma and surgery within 30days; 4. Taking the following oral medications: Indications for anticoagulation treatment(such as atrial fibrillation, mitral stenosis or prosthetic heart valve replacement) or antiplatelet treatment. Any oral or parenteral anticoagulant such as low molecular weight heparin was administered within 30 days of screening; potent CYP3A4 receptor inhibitors (ketoconazole, clarithromycin, and itracon) CYP3A substrate with a narrow therapeutic index (cyclosporine and quinidine) potent CYP3A inducer (rifampicin, phenytoin and carbamazepine) or non-steroidal anti-inflammatory drugs (NSAID) were used within 2 weeks prior to screening; 5. A clear history of drug allergy (clopidogrel, ticagrelor); 6. Participated in other drug or device clinical trials within 3 months prior to enrollment; 7. History of alcohol or drug addiction or heavy smoking in the last year; 8. Other situations are thought not suitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adenosine plasma concentration;Adenosine uptake by RBC;ticagrelor and AR-C124910XX concentrations ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Calibrated Automated Thrombogram;PT, APTT, TT, FIB;platelet function; | — |
Countries
China
Contacts
Public ContactLi-Ping Ma
Shanghai Changhai Hospital
Outcome results
None listed